FUJIFILM Diosynth Biotechnologies’ Post

🔬 Glimpse the Future of Healthcare through the lens of #Theranostics! 🌟 🔍💊 The revolutionary field of #theranostics merges diagnostics and therapy to reshape precision medicine. 🚀 Future Vistas Because of their precision, theranostics reduce the risk of harming nearby healthy tissues. The number of #FDA-approved theranostic procedures is on the rise, as they are set to enhance diagnostic accuracy, optimise treatments, and minimise side effects. 🔍 Read Rosanna Santella's article here: https://lnkd.in/dS5G-_yt 💊🔮 #HealthcareInnovation #PrecisionMedicine

If you want to learn more about personalized medicine, take a look at my last article on #theranostics for Kvalito Consulting Group 🔬🧬

How to make PCLS (precision-cut lung slices) is one of the most common questions I get. Read my latest blog article for tips and tricks. Respiratory research using PCLS is expanding, and I'm here for any help you may need.

You may find this article helpful and it is important you aware different regulatory knowledge and trend ARPA - Asia Regulatory Professionals Association

🚀 Exciting News from Roche! 🚀 Today, Roche's disclosed promising Phase I study results for CT-996, their innovative oral GLP-1 receptor agonist aimed at tackling obesity. The study showcased that CT-996, a once-daily small molecule, led to a significant placebo-adjusted mean weight loss of 6.1% in just four weeks. What's more reassuring is that its safety and tolerability are in line with other drugs of its class, with no unexpected safety issues cropping up. This breakthrough positions CT-996 as not just a potential treatment for glycaemic control and weight loss, but also as an oral option for weight maintenance following initial weight reduction using injectables. Stay tuned as full data will be unveiled at an upcoming medical conference. This could be a game-changer in the management of obesity, offering a convenient oral alternative to existing treatments. #Roche #InnovationInHealthcare #ObesityTreatment #GLP1Agonist #CT996 #HealthTech #MedicalBreakthrough 🔍 Keep an eye on this space for updates on how Roche continues to transform healthcare with cutting-edge research and development!

🔎 Want to learn more about Microvesicles? What are their clinical interests? Listen to Prof. françoise dignat-george and Dr. romaric lacroix speak about Microparticles (MVs) as an emerging biomarker with multifaced clinical indications.  👉 https://lnkd.in/e5aynjtE   MVs have been described as procoagulant entities since their first report due to the presence of negative procoagulant phospholipids – mainly phosphatidylserine – and/or tissue factor at their surface. Learn more 👉 https://lnkd.in/d5cGvir7 #microvesicles #diagnosis #clinical #clinicalstudies #thrombosis #webinar #educational

We are pleased to share our most recent publication, where we share the cost-effectiveness model we've developed to evaluate the efficacy and economic viability of Digital Variance Angiography (DVA) over Digital Subtraction Angiography (DSA) for lower limb x-ray angiography from the perspective of the English National Health Service (NHS). Utilizing a two-part economic model that integrates both a decision tree and a Markov model, this analysis delved into the financial and health outcomes related to the use of DVA, particularly its effects on the onset of acute kidney injury (AKI), chronic kidney disease, and radiation-induced cancer across a patient's lifetime. The model's base-case results revealed that DVA not only reduces costs by £309 per patient but also enhances quality-adjusted life years (QALYs) by 0.025. This improvement is attributed mainly to the diminished risk of contrast-associated AKI and a lower risk of developing carcinoma. The team at Optimax Access enjoyed collaborating with Kinepict Health Ltd. and Device Access UK Ltd teams, including Lorenzo Patrone. https://lnkd.in/evuqztTA The Evidence Base® Amir Ansaripour Mehdi Javanbakht (Ph.D.) Eoin Moloney #heor #healtheconomics #marketaccess #pharmaceuticals #costeffectiveness

At Goffin Molecular Technologies, we continue to support healthcare professionals with advanced diagnostic solutions, such as the HLA-B27 RealFast™ Assay from ViennaLab. Why choose the HLA-B27 RealFast™ Assay? It offers: -         High accuracy in real-time PCR testing for HLA-B27 allele detection. -         Essential aid in confirming diagnoses of conditions like ankylosing spondylitis (axial spondyloarthritis), where vertebrae can fuse, leading to reduced spinal flexibility and possibly a hunched posture, and difficulty in deep breathing if ribs are affected. Also crucial for reactive arthritis, juvenile rheumatoid arthritis, and anterior uveitis. -         Efficient identification of the majority of disease-relevant HLA-B27 subtypes. -         Optimized components including gene-specific primers, dual-labeled hydrolysis probes, and a robust buffer system. The prevalence of the HLA-B27 variant in patients with ankylosing spondylitis, coupled with its significant but lesser association in other spondyloarthritis subsets, underscores the assay's value in differential diagnosis. For details or to discuss how the HLA-B27 RealFast™ Assay can benefit your practice, contact our sales department at jarno@goffinmt.com. Let’s enhance patient care together through precise diagnostics. #HLAB27 #RealFastAssay #ViennaLab #MolecularDiagnostics #Healthcare #GoffinMolecularTechnologies

Congratulations to our portfolio company CDR-Life Inc. and Boehringer Ingelheim, who are joining forces to develop new treatment to preserve the vision of people suffering from geographic atrophy.   The two companies have just announced the initiation of Phase 1 evaluation for BI 771716, an antibody fragment-based treatment developed with technology licensed from CDR-Life Inc.   Geographic atrophy is a chronic and progressive, irreversible retinal disease that occurs in people with late-stage dry age-related macular degeneration (AMD), impacting their ability to see. More than 5 million people worldwide suffer from it, with over 40% legally blind. This disease worsens with age.   BI 771716 could potentially transform the lives of these millions of people living with this condition 👏   Learn more 👉 https://lnkd.in/eWyv8p3A   #FasterForThePatient #ophthalmology #innovation #biopharma #lifesciences

Having worked on this paper as an internship deliverable during my summer internship at IQVIA, it is surreal to finally see it in fruition! 😍 This Companion Diagnostics (CDxs) paper is part of IQVIA's thought leadership on the future of Precision Medicine, and where the region (APAC) is at currently in our regulation of CDxs. As a brief introduction, CDxs improve patient outcomes by helping to match treatments having genetic undertones with patients having the specific genetic predisposition that responds to the treatment. It is a burgeoning realm that is currently focused on oncology, since many cancers are tied to genetic mutations. Regulatory concerns are a major hurdle for companies manufacturing CDxs, as countries may have different requirements governing this class of Medical Devices -- affecting things like market access and patient accessibility. Do give the blog a read to learn more about Companion Diagnostics! 😀